Related Experiment Videos
[Effect of imipenem/cilastatin combined with vancomycin for MRSA infection]
T Fukabori1, K Mizobuchi, M Nakamura
1Department of Internal Medicine, Shakaihoken Kobe Central Hospital.
Abstract:
Therapeutic efficacy of the combined regimen, imipenem/cilastatin (IPM/CS) plus vancomycin (VCM), was examined in a total of 13 patients infected with MRSA (10 patients with pneumonia, 2 with sepsis and 1 with urinary tract infection). Based on the results of determination of FIC indices, in vitro combined effects were synergistic in 4 strains and additive in 3 strains. There was, however, no apparent correlation between the in vitro combined effect in terms of FIC index and clinical outcome. No side effects or abnormal laboratory findings were observed. The average daily doses of IPM/CS and VCM were 1.2 g and 1.25 g and the average administration periods were 17.5 and 14.9 days, respectively. The present results suggested that simultaneous use of IPM/CS and VCM at the standard doses could yield an enhancement of both bacteriological and clinical efficacies in treatment of the patients with MRSA infection.
Insights
This study investigated imipenem/cilastatin (IPM/CS) plus vancomycin (VCM) for MRSA infections. The combination therapy showed potential for enhanced bacteriological and clinical efficacy in patients, with no observed adverse effects.
Area of Science:
- Infectious Diseases
- Pharmacology
- Clinical Microbiology
Background:
- Methicillin-resistant Staphylococcus aureus (MRSA) poses a significant challenge in healthcare settings.
- Effective treatment strategies for MRSA infections are crucial to improve patient outcomes.
- The combination of imipenem/cilastatin (IPM/CS) and vancomycin (VCM) is explored for its potential synergistic effects.
Purpose of the Study:
- To evaluate the therapeutic efficacy of the combined regimen of imipenem/cilastatin (IPM/CS) plus vancomycin (VCM) in patients with MRSA infections.
- To assess the in vitro combined effects of IPM/CS and VCM against MRSA strains.
- To correlate in vitro findings with clinical outcomes in a small patient cohort.
Main Methods:
- A total of 13 patients with MRSA infections (pneumonia, sepsis, urinary tract infection) were treated with IPM/CS plus VCM.
- In vitro studies determined the fractional inhibitory concentration (FIC) indices to assess combined effects.
- Clinical outcomes, including bacteriological and clinical efficacies, and adverse events were monitored.
Main Results:
- In vitro, the combined regimen exhibited synergistic effects in 4 strains and additive effects in 3 strains.
- No clear correlation was found between in vitro synergistic effects and clinical outcomes.
- No side effects or abnormal laboratory findings were reported during the treatment period.
Conclusions:
- The combined use of imipenem/cilastatin (IPM/CS) and vancomycin (VCM) at standard doses may enhance bacteriological and clinical efficacy in treating MRSA infections.
- Further research with larger cohorts is warranted to confirm these findings.
- The combination appears safe and well-tolerated in the studied patient population.